Skip to main content

IntelGenx Technologies Corp.

IGXTDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001098880

IntelGenx Technologies Corp. was delisted in 2024; its insiders filed their last Form 4 on May 3, 2024; 1 institution reported holding it in 13F filings for Q1 2024, worth $414 in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by IntelGenx Technologies Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for IntelGenx Technologies Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for IntelGenx Technologies Corp.
NameTitleLast reported holdingLast filingFilings, past year
ATAI Life Sciences AG10% Owner–May 3, 20240
ATAI Life Sciences N.V.10% Owner–May 3, 20240
Zerbe Horst GDirector368,064Jan 31, 20240
Melchers Bernd JosefDirector–Jan 31, 20240
Godin AndrePresident and CFO308,399Jan 31, 20240
Mayr ClemensDirector–Jan 31, 20240
Paiement NadineVP R & D of IntelGenx Corp.–Jan 31, 20240
Nawacki MarkDirector–Jan 31, 20240
Kenny TommySVP IP Legal Affairs Subsid138,500Jan 31, 20240
Kalayajian KarenVP, Finance & Admin of Subs.–Jan 31, 20240
Gorham DwightCEO–Jan 31, 20240
Pourhassan Zenoz NinaVP, Quality Operations of Subs–Jan 31, 20240
Zerbe IngridCorporate Secretary685,238Jan 31, 20230
Matzen DanaVP Business & Corp. Dev75,000Jan 31, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 12, 2024 (view filing)9:36 PM ETNov 28, 2023105 daysLateATAI Life Sciences AG and 1 other10% OwnerPPurchase+8.11M–––16.1M afterDerivative2 lots
Sep 5, 2023 (view filing)9:00 PM ETAug 315 daysATAI Life Sciences AG and 1 other10% OwnerPPurchase+24.0M–––12.0M afterDerivative2 lots
Oct 3, 2022 (view filing)8:47 AM ETSep 303 daysZerbe Horst GChief Executive OfficerPPurchaseCommon Stock, 0.00001 p.V+19.0K$0.1251+$2.38K+5.4%368.1K after2 lots
Oct 3, 2022 (view filing)8:12 AM ETSep 294 daysGodin AndrePresident and CFOPPurchaseCommon Stock, 0.00001 p.V.+5.00K$0.124+$620+1.6%308.4K after
Sep 29, 2022 (view filing)8:01 AM ETSep 27-282 daysGodin AndrePresident and CFOPPurchaseCommon Stock, 0.00001 p.V.+10.0K$0.1346+$1.35K+3.4%303.4K after2 lots
Sep 28, 2022 (view filing)8:00 AM ETSep 262 daysKenny TommyVP IP Legal Affairs-SubsidiaryPPurchaseCommon Stock, 0.00001 p.V.+19.0K$0.135+$2.56K+15.9%138.5K after
Sep 26, 2022 (view filing)8:27 AM ETSep 224 daysKenny TommyVP IP Legal Affairs-SubsidiaryPPurchaseCommon Stock, 0.00001 p.V.+23.5K$0.145+$3.41K+27.3%109.5K after
Sep 26, 2022 (view filing)8:27 AM ETSep 22-234 daysKenny TommyVP IP Legal Affairs-SubsidiaryPPurchaseCommon Stock, 0.00001 p.V+10.0K$0.1472+$1.47K+9.1%119.5K after2 lots
Sep 22, 2022 (view filing)4:15 PM ETSep 211 dayGodin AndrePresident and CFOPPurchaseCommon Stock, 0.00001 p.V+20.0K$0.134+$2.68K+7.3%293.4K after
Sep 22, 2022 (view filing)9:26 AM ETSep 211 dayMatzen DanaVP BD & Corp.Dev.of SubsidiaryPPurchaseCommon Stock, 0.00001 p.V.+25.0K$0.138+$3.45K+50.0%75.0K after
Mar 31, 2022 (view filing)4:00 PM ETMar 301 dayMatzen DanaVP BD & Corp.Dev.of SubsidiaryPPurchaseCommon Stock, 0.00001 p.V.+25.0K$0.265+$6.63K+100.0%50.0K after